Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.

Herrmann O, Kuepper MK, Bütow M, Costa IG, Appelmann I, Beier F, Luedde T, Braunschweig T, Koschmieder S, Brümmendorf TH, Schemionek M.

BMC Cancer. 2019 Jul 4;19(1):658. doi: 10.1186/s12885-019-5871-2.

2.

Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling.

Kuepper MK, Bütow M, Herrmann O, Ziemons J, Chatain N, Maurer A, Kirschner M, Maié T, Costa IG, Eschweiler J, Koschmieder S, Brümmendorf TH, Müller-Newen G, Schemionek M.

Leukemia. 2019 Aug;33(8):1964-1977. doi: 10.1038/s41375-019-0427-7. Epub 2019 Mar 6.

PMID:
30842608
3.

Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP.

Hatzl S, Geiger O, Kuepper MK, Caraffini V, Seime T, Furlan T, Nussbaumer E, Wieser R, Pichler M, Scheideler M, Nowek K, Jongen-Lavrencic M, Quehenberger F, Wölfler A, Troppmair J, Sill H, Zebisch A.

Cancer Res. 2016 Jun 15;76(12):3644-54. doi: 10.1158/0008-5472.CAN-15-3049. Epub 2016 Apr 15.

Supplemental Content

Loading ...
Support Center